Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 2/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510653 | 0.90 | GLP1R (0.51) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL29381722 | 0.90 | AGTR2 (0.50) | OPRD1ANPEPLNPEPCTSD | |
| SCHEMBL30426861 | 0.87 | OPRD1 (0.56) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30646307 | 0.87 | OPRD1 (0.52) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30510650 | 0.87 | OPRD1 (0.49) | OPRD1OPRM1OPRK1ANPEPLNPEP | |
| SCHEMBL30974312 | 0.86 | OPRD1 (0.63) | OPRD1OPRM1OPRK1GLP1R | |
| SCHEMBL30662034 | 0.86 | GLP1R (0.53) | OPRD1GLP1R | |
| SCHEMBL30874967 | 0.86 | GLP1R (0.52) | OPRD1GLP1R | |
| SCHEMBL29705076 | 0.86 | OPRD1 (0.45) | OPRD1OPRM1OPRK1ANPEPLNPEP | |
| SCHEMBL30901852 | 0.85 | OPRD1 (0.54) | OPRD1OPRM1OPRK1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | CORNELL UNIVERSITY (US) | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | HSPA9, OPA1, ARG2 | OPRD1 1112/4885OPRM1 1771/4885OPRK1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.